

# LITHUANIA

Number of new cases

**16 413**

Number of deaths

**8 349**

Number of prevalent cases (5-year)

**50 896**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	1 231 601	1 430 103	2 661 704
<b>Incidence*</b>			
Number of new cancer cases	9 245	7 168	16 413
Age-standardized incidence rate	391.3	224.0	287.9
Risk of developing cancer before the age of 75 years (cum. risk %)	38.8	22.2	29.3
Top 3 leading cancers (ranked by cases)**	Prostate Lung Colorectum	Breast Colorectum Corpus uteri	Prostate Breast Colorectum
<b>Mortality*</b>			
Number of cancer deaths	4 639	3 710	8 349
Age-standardized mortality rate	181.6	88.7	125.0
Risk of dying from cancer before the age of 75 years (cum. risk %)	19.7	9.7	13.9
Top 3 leading cancers (ranked by deaths)**	Lung Prostate Colorectum	Breast Colorectum Lung	Lung Colorectum Stomach
<b>Prevalence*</b>			
5-year prevalent cases	28 314	22 582	50 896



## Top 5 most frequent cancers\*\*


**Males**



Rank	Cancer site	Number of cases	Percent
1st	Prostate	3 208	34.7%
2nd	Lung	1 104	11.9%
3rd	Colorectum	770	8.3%
4th	Stomach	460	5.0%
5th	Bladder	437	4.7%
-	Others	3 266	35.3%

Number of new cases in 2022, males, all ages


**Females**



Rank	Cancer site	Number of cases	Percent
1st	Breast	1 719	24.0%
2nd	Colorectum	736	10.3%
3rd	Corpus uteri	684	9.5%
4th	Lung	390	5.4%
5th	Ovary	366	5.1%
-	Others	3 273	45.7%

Number of new cases in 2022, females, all ages

**Both sexes**



Rank	Cancer site	Number of cases	Percent
1st	Prostate	3 208	19.5%
2nd	Breast	1 719	10.5%
3rd	Colorectum	1 506	9.2%
4th	Lung	1 494	9.1%
5th	Stomach	757	4.6%
-	Others	7 729	47.1%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Prostate	3 208	1	19.5	16.8	545	5	6.5	1.8	13 549	1100.1
Breast	1 719	2	10.5	6.9	515	6	6.2	1.7	7 135	498.9
Colorectum	1 506	3	9.2	2.7	938	2	11.2	1.4	4 706	176.8
Lung	1 494	4	9.1	3.1	1 241	1	14.9	2.5	1 882	70.7
Stomach	757	5	4.6	1.4	597	3	7.2	1.1	1 044	39.2
Corpus uteri	684	6	4.2	2.6	153	17	1.8	0.43	2 718	190.1
Kidney	642	7	3.9	1.4	294	7	3.5	0.51	2 085	78.3
Pancreas	605	8	3.7	0.97	565	4	6.8	0.98	494	18.6
Bladder	536	9	3.3	0.96	267	9	3.2	0.34	1 790	67.3
Leukaemia	473	10	2.9	0.85	269	8	3.2	0.39	1 387	52.1
Ovary	366	11	2.2	1.4	241	12	2.9	0.80	1 118	78.2
Melanoma	350	12	2.1	0.75	120	20	1.4	0.21	1 335	50.2
Thyroid	336	13	2.0	0.89	22	25	0.26	0.04	1 305	49.0
Brain CNS	312	14	1.9	0.68	253	11	3.0	0.55	1 250	47.0
NHL	306	15	1.9	0.64	161	15	1.9	0.24	1 026	38.6
Cervix uteri	296	16	1.8	1.3	191	14	2.3	0.73	1 039	72.7
Liver	292	17	1.8	0.58	266	10	3.2	0.55	349	13.1
Lip, oral cavity	257	18	1.6	0.61	157	16	1.9	0.37	858	32.2
Oesophagus	234	19	1.4	0.54	213	13	2.6	0.49	332	12.5
Larynx	190	20	1.2	0.47	127	19	1.5	0.30	694	26.1
Multiple myeloma	179	21	1.1	0.37	130	18	1.6	0.22	559	21.0
Hypopharynx	121	22	0.74	0.30	81	21	0.97	0.20	270	10.1
Oropharynx	110	23	0.67	0.28	72	22	0.86	0.18	362	13.6
Gallbladder	57	24	0.35	0.08	44	23	0.53	0.06	62	2.3
Vulva	46	25	0.28	0.12	27	24	0.32	0.03	137	9.6
Hodgkin lymphoma	40	26	0.24	0.13	11	28	0.13	0.02	173	6.5
Salivary glands	35	27	0.21	0.07	20	26	0.24	0.04	121	4.6
Testis	32	28	0.20	0.20	3	32	0.04	0.02	143	11.6
Penis	27	29	0.17	0.13	9	29	0.11	0.03	94	7.6
Nasopharynx	20	30	0.12	0.05	14	27	0.17	0.02	63	2.4
Vagina	13	31	0.08	0.04	7	30	0.08	0.00	33	2.3
Mesothelioma	9	32	0.06	0.01	7	30	0.08	0.02	11	0.41
<b>All cancers</b>	<b>16 413</b>	-	-	<b>29.3</b>	<b>8 349</b>	-	-	<b>13.9</b>	<b>50 896</b>	-
<b>All cancers excl. NMSC</b>	<b>16 119</b>	-	-	<b>29.1</b>	<b>8 294</b>	-	-	<b>13.8</b>	<b>49 908</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** [ {"dt\_list": "National cancer registry" } ]  
**Method:** National (or sub-national with coverage greater than 50%) rates projected to 2022

### Mortality

**Country-specific data source:** National (WHO)  
**Method:** National rates projected to 2022

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

